ALPHAMAB ONCOLOGY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.45 HKD | +0.91% |
|
+3.01% | -32.98% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Alphamab Oncology is an investment holding company primarily engaged in the biopharmaceutical business. The Company is a full-industry chain enterprise specializing in research, development, manufacture, and commercialization of innovative tumor immunobiology macromolecular targeted drugs. The Company has bio-innovation drug development technology platform, including protein engineering platform, multi-functional antibody development platform and antibody screening platform. The Company operates its businesses in both domestic and overseas markets.
Calendar
2024-06-11
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
4
Last Close Price
4.08
CNY
Average target price
4.211
CNY
Spread / Average Target
+3.22%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -32.98% | 543M | |
| +4.09% | 43.84B | |
| +46.85% | 41.25B | |
| +9.45% | 41.68B | |
| -10.92% | 27.04B | |
| +9.32% | 25.53B | |
| -24.87% | 18.18B | |
| +29.70% | 12.29B | |
| +1.28% | 12.29B | |
| +7.78% | 11.15B |
- Stock Market
- Equities
- 9966 Stock
- News Alphamab Oncology
- Alphamab Oncology : Says Candidate Cancer Drugs Show Initial Efficacy in Clinical Trials
